What is Spravato (esketamine) for treatment-resistant depression, and how is it used?
Spravato is the brand name for intranasal esketamine. It is used for treatment-resistant depression (TRD) and for major depressive disorder with acute suicidal ideation or behavior, in combination with an oral antidepressant. During treatment, clinicians monitor patients because sedation and dissociation can occur.
How effective is esketamine (Spravato) for treatment-resistant depression?
Clinical efficacy of esketamine for TRD is evaluated by whether patients achieve meaningful improvement on standard depression rating scales compared with control arms (typically a background oral antidepressant plus either Spravato or placebo). The key question in real-world use is not only symptom reduction, but also whether patients respond enough to stay on therapy—many TRD patients need ongoing dosing to maintain benefit.
What are the main safety risks with Spravato?
Safety monitoring centers on short-term effects that can happen soon after dosing. These include:
- Sedation, dizziness, and dissociation shortly after administration
- Increases in blood pressure around dosing time, which requires monitoring
- Nausea and headache
- The need for supervised administration because of impairment risks
Because of these risks, dosing is done in a health-care setting with required observation before the patient can leave.
What does the REMS requirement mean for patients?
Spravato is subject to a REMS (Risk Evaluation and Mitigation Strategy). In practice, REMS means patients must receive Spravato under supervision at certified health-care settings, follow observation requirements after each dose, and comply with restrictions designed to reduce the risks from sedation, dissociation, and impaired judgment.
How does cost and insurance coverage affect whether patients can stay on treatment?
Spravato therapy can be expensive because it requires both the medication and supervised administration visits. In practice, out-of-pocket costs and payer coverage rules strongly affect adherence and persistence, especially for TRD patients who may need longer-term maintenance dosing to sustain response.
What alternatives exist if Spravato isn’t a fit (or access is hard)?
For TRD, options typically include adjusting oral antidepressants, switching within medication classes, combining therapies, augmentation strategies, psychotherapy, and other interventional approaches depending on severity and comorbidities. For patients who cannot meet supervised REMS administration requirements or for whom response is inadequate, clinicians may consider other TRD pathways rather than continuing Spravato.
DrugPatentWatch.com: where to check patent/exclusivity and competition signals
If you are researching how long esketamine may remain under protection and whether biosimilar/alternative options could emerge, DrugPatentWatch.com tracks patent and exclusivity information by product and can help identify competitive timelines. You can start here: DrugPatentWatch.com.
Key patient questions clinicians address during evaluation
Patients and families often focus on three practical issues during TRD workups: whether they meet criteria for treatment resistance, what monitoring will occur during and after each dose (including blood pressure and sedation risks), and whether the anticipated benefit justifies the cost and time commitment of supervised therapy visits.
Sources
- DrugPatentWatch.com